Raman Sankar
Neurodevelopmental Disabilities · Los Angeles, CANPI 1376629063
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $722,204 of the $1,100,083 with a category attached, or 65.6%. 25 manufacturers reported payments, led by UCB, Inc. at 31.5% of the total. Among neurodevelopmental disabilities clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,406 payments — averaging $782.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- UCB, Inc.$346K
- SK Life Science, Inc.$162K
- Neurelis, Inc.$155K
- Jazz Pharmaceuticals Inc.$110K
- Eisai Inc.$61K
- Biomarin Pharmaceutical Inc.$56K
- plus $210K from 19 others
Across 5 payments — averaging $2930.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- SK Life Science, Inc.$11K
- Takeda Pharmaceuticals U.S.A., Inc.$3K
- UCB, Inc.$420
What the payments were for
- Consulting fees$155,17814%
- Speaking & faculty fees$722,20466%
- Travel & lodging$187,70317%
- Food & beverage$34,9443%
- Education$530%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| UCB, Inc. | 575 | $346,049 |
| SK Life Science, Inc. | 178 | $161,708 |
| Neurelis, Inc. | 151 | $154,988 |
| Jazz Pharmaceuticals Inc. | 143 | $109,912 |
| Eisai Inc. | 65 | $60,709 |
| Biomarin Pharmaceutical Inc. | 57 | $56,380 |
| Livanova USA, Inc. | 56 | $50,833 |
| Greenwich Biosciences, Inc. | 49 | $40,573 |
| Sunovion Pharmaceuticals Inc. | 22 | $19,114 |
| Vertex | 12 | $17,735 |
| Supernus Pharmaceuticals, Inc. | 18 | $15,563 |
| Aquestive Therapeutics, Inc. | 28 | $15,485 |
| UCB SA | 3 | $12,730 |
| Biogen | 10 | $12,502 |
| Zogenix Inc. | 17 | $9,783 |
| Radius Health, Inc. | 4 | $7,525 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $3,000 |
| Biocodex, Inc. | 5 | $1,969 |
| Catalyst Pharmaceuticals, Inc. | 2 | $1,727 |
| Aprecia Pharmaceuticals, LLC | 1 | $1,160 |
| Immedica Pharma US, Inc. | 3 | $317 |
| Lundbeck LLC | 1 | $160 |
| Pyros Pharmaceuticals, Inc. | 1 | $134 |
| AstraZeneca | 1 | $21 |
| Travere Therapeutics, Inc. | 2 | $6 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Fintepla$288,445
- VALTOCO$153,276
- XCOPRI$151,282
- Epidiolex$147,352
- Brineura$48,333
- Fycompa$44,556
- VNS THERAPY SENTIVA MODEL 1000 GENERATOR$36,554
- Briviact$28,805
- Banzel$20,891
- APTIOM$18,853
- OXTELLAR XR$15,501
- SYMPAZAN$15,251
- Vimpat$14,636
- VNS Therapy$13,566
- Nayzilam$8,010
- Cenobamate$3,425
- DIACOMIT$1,969
- Spritam$1,160
- ZTALMY$289
- VIGPODER$134
How this compares
$1,100,083 in reported general payments places this provider in the 95th percentile of 21 neurodevelopmental disabilities providers in California.
See all neurodevelopmental disabilities providers in California →
Other neurodevelopmental disabilities in Los Angeles
- William ShieldsLos Angeles$5.9M
- Joyce WuLos Angeles$23K
- Jason LernerLos Angeles$11K
- Christopher GizaLos Angeles$7K
- Ying PengLadera Ranch$18K
- Elysa MarcoSan Francisco$10K
- Paul ChretienSacramento$4K
- Sabrina CarterSanta Barbara$2K
- Anuja JindalSan Diego$1K
- Rebecca GarfinkleLaguna Niguel$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.